One-Year Outcomes of Preserflo Microshunt for Primary Open Angle Glaucoma: A Systematic Review and Meta-Analysis.
AI Summary
This meta-analysis found the Preserflo Microshunt significantly lowers intraocular pressure and medication needs in open-angle glaucoma patients at 12 months, offering a new treatment option.
Abstract
Précis: This systematic review and meta-analysis concludes that the PreserFlo Microshunt glaucoma drainage device significantly reduces intraocular pressure in primary open angle glaucoma patients at 12 months postinsertion.
Purpose
A systematic review and meta-analysis on the effect of the PRESERFLO MicroShunt (PF-MS) on intraocular pressure (IOP) at 12 months has been conducted.
Method
The PubMed/MEDLINE, Embase, CENTRAL, Google Scholar, Scopus, and Web of Science databases were searched. Inclusion criteria required a diagnosis of open angle glaucoma, PF-MS insertion, and examination of IOP over time. Meta-analyses were conducted on the primary outcome of IOP and the secondary outcome of glaucoma medication regime. Adverse events were also noted.
Results
Fourteen studies were identified for inclusion in the meta-analyses, of which none had a high risk of bias. The meta-analyses found a significant mean reduction in IOP of 9.07 mm Hg (95% CI: 7.88-10.25; P <0.0001) and a significant mean reduction in mean glaucoma medication requirement of 2.37 medications (95% CI: 2.15-2.60; P <0.0001). Hypotony and hyphaema are common early complications.
Conclusions
The PF-MS device significantly reduced both IOP and glaucoma medication requirement at 12 months postinsertion in individuals with open angle glaucoma without a significant adverse event burden. Further research is required to determine the economic and environmental effects of widely implementing the PF-MS device into clinical practice.
MeSH Terms
Shields Classification
Key Concepts4
The PreserFlo Microshunt glaucoma drainage device significantly reduces intraocular pressure in primary open angle glaucoma patients at 12 months postinsertion.
A systematic review and meta-analysis of 14 studies found a significant mean reduction in intraocular pressure (IOP) of 9.07 mm Hg (95% CI: 7.88-10.25; P <0.0001) with the PRESERFLO MicroShunt (PF-MS) device at 12 months postinsertion in individuals with open angle glaucoma.
A systematic review and meta-analysis of 14 studies found a significant mean reduction in mean glaucoma medication requirement of 2.37 medications (95% CI: 2.15-2.60; P <0.0001) with the PRESERFLO MicroShunt (PF-MS) device at 12 months postinsertion in individuals with open angle glaucoma.
Hypotony and hyphaema are common early complications associated with the PreserFlo Microshunt glaucoma drainage device.
Related Articles5
Changes in intraocular pressure during reading or writing on smartphones in patients with normal-tension glaucoma.
Observational StudyThe effect of trabeculectomy on the intraocular pressure of the unoperated fellow eye.
Cohort StudyConjunctival characteristics in primary open-angle glaucoma and modifications induced by trabeculectomy with mitomycin C: an in vivo confocal microscopy study.
Case-Control StudyEffect of trabeculectomy on intraocular pressure fluctuation with postural change in eyes with open-angle glaucoma.
Observational StudyThe singapore 5-Fluorouracil trabeculectomy study: effects on intraocular pressure control and disease progression at 3 years.
Randomized Controlled TrialIs this article assigned to the wrong chapter(s)? Let us know.